Revolution Medicines, Inc. (rvmd)
RVMD — Company Overview
Revolution Medicines, Inc. (RVMD) trades on NMS as part of the Healthcare peer group (Biotechnology).
| Ticker | RVMD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $40.88B |
| Last price | $190.74 |
| Size category | Large Cap |
RVMD — Business Description
RVMD represents a Biotechnology business in the Healthcare segment. Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registratio…
Official website: https://www.revmed.com.
RVMD — Investment Thesis
At a high level, RVMD offers exposure to Healthcare with metrics outlined below from public market data.
- Equity market capitalization is approximately $40.88B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
RVMD — Financial Health
Key financial health indicators for Revolution Medicines, Inc. are derived exclusively from public data — no proprietary estimates.
Profit margin near 0.0% leaves a narrower cushion versus higher-margin peers. Negative free cash flow of $-711.61M may require careful capital allocation.
| Forward P/E | -31.71× |
| Price / Book | 15.68× |
| Gross margin | 0.0% |
| Operating margin | 0.0% |
| Profit margin | 0.0% |
| Return on equity | -79.1% |
| Debt / Equity | 45.68 |
| Free cash flow | $-711.61M |
RVMD — Growth Outlook
Growth outlook for Revolution Medicines, Inc. (RVMD) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Price is 15.0% below the 52-week high.
RVMD — Competitive Position
Revolution Medicines, Inc. (RVMD) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $40.88B places RVMD among large-cap peers.
- Gross margin of 0.0% should be benchmarked against direct competitors.
RVMD — Strengths
Strengths for Revolution Medicines, Inc. (RVMD) inferred from public financial metrics:
- Moderate leverage (debt/equity 45.68).
- Large Cap scale ($40.88B) may provide distribution and funding advantages.
RVMD — Weaknesses
Weaknesses and pressure points for Revolution Medicines, Inc. (RVMD) based on available data:
- Thin profit margin (0.0%).
- Negative free cash flow ($-711.61M).
- High beta (1.41) amplifies market swings.
RVMD — Opportunities
- Opportunities depend on industry trends and execution — monitor quarterly filings and guidance.
RVMD — Risks
- Beta of 1.41 implies above-market volatility.
- Thin margins leave less room for operational missteps.
RVMD — Summary
Revolution Medicines, Inc. (RVMD) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $190.74 with market cap $40.88B. Notable strengths include moderate leverage (debt/equity 45.68). Key watch items include thin profit margin (0.0%). Premium Terminal tools for Revolution Medicines, Inc. add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open RVMD in Vest Terminal
Access live data, filings, ownership, and analysis for Revolution Medicines, Inc..
Revolution Medicines, Inc. FAQ
What does Revolution Medicines, Inc. (RVMD) do?
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination wit…
What is RVMD's P/E ratio?
Revolution Medicines, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does RVMD pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is RVMD in?
Revolution Medicines, Inc. is classified in Healthcare (Biotechnology) on NMS.
What is RVMD's market capitalization?
Approximate market cap: $40.88B.
What are the main risks for RVMD?
Key risks include above-average volatility (beta 1.41), among factors on this page.
What are the strengths of RVMD?
Potential positives include moderate leverage (debt/equity 45.68), large cap scale ($40.88b) may provide distribution and funding advantages.
Where can I get analyst estimates for RVMD?
Public analyst price targets and consensus for Revolution Medicines, Inc. are on the free /stocks/rvmd/estimates page. Deeper estimate history and models are available in Vest Terminal.